1 of 6

Poster #: P1007�Evaluation of transmural healing in patients with moderately to severely active Crohn’s disease shows early efficacy of vedolizumab: VECTORS week 14 interim analysis

V. Jairath, S.K. Vuyyuru, C. Ma, G. Zou, B. Neustifter, C. Agboton, I. Romo Bautista, J.J. Wu, H.J. Jiang, M. Allocca, Y.K. An, J. Begun, R.V. Bryant, S. Danese, M.C. Dubinsky, M. Freire, K.L. Novak, R. Panaccione, A. Pudipeddi, D.T. Rubin, B.E. Sands, M.P. Sparrow, S.A. Taylor, K.B. Gecse, C. Maaser, B.G. Feagan, R.L. Wilkens

​

Slides compiled by Dr. Jeffrey McCurdy

​

2 of 6

Introduction

Background & Objectives

    • The optimal treat-to-target strategy for Crohn’s disease (CD) remains unknown
    • Transmural healing (TMH) may improve outcomes compared with clinical and endoscopic healing
    • Objective: This interim analysis of the VECTORS clinical trial program evaluated week 14 IUS outcomes in patients with CD treated with vedolizumab (VDZ).

CD, Crohn’s disease; TMH, transmural healing; VDZ, vedolizumab; IUS, intestinal ultrasound; CS, corticosteroids.�Jairath V et al. ECCO 2026; (Abstract citation ID: jjaf231.1188, P1007).

2

Methods

    • Design: Multicenter, randomized trial comparing two treat-2-target strategies in patients with CD treated with VDZ :
    • TMH + clinical + biochemical remission
    • Clinical + biochemical remission
    • Follow-up: Weeks 22, 30, and 38. Treatment optimization (CS, VDZ optimization or switch to alternate therapy) if target not achieved.
    • Primary outcome: Week 48 CS-free endoscopic remission
    • Outcome for this interim analysis is week 14 TMH (group 1)

Follow-up & Assessments

3 of 6

Methods

CD, Crohn’s disease; VDZ, vedolizumab; CS, corticosteroids; IUS, intestinal ultrasound; TMH, transmural healing.�Jairath V et al. ECCO 2026; (Abstract citation ID: jjaf231.1188, P1007).

Week 14 IUS outcomes

4 of 6

Results:

    • 54 of planned 304 participants were randomised and treated with VDZ

​

    • 41/54 reached week 14

​

    • Analysis will assess the patients who underwent week 14 IUS from group 1

VDZ, vedolizumab; CDAI, Crohn’s Disease Activity Index; SES-CD, Simple Endoscopic Score for Crohn’s Disease; CRP, C-reactive protein; FCP, faecal calprotectin; CS, corticosteroids.�Jairath V et al. ECCO 2026; (Abstract citation ID: jjaf231.1188, P1007).

4

​

Treatment Target Groups

Characteristics

Group 1a

(N=28)

Group 2b

(N=26)

Male, n (%)

20 (71.4)

18 (69.2)

Age (y), mean (SD)

38 (17)

38 (16)

CDAI score, mean (SD)

296 (60)

295 (58)

SES-CD score, mean (SD)

10.8 (6.4)

11.0 (5.6)

Disease duration (y), median (min, max)

2.3 (0.4, 39.6)

5.6 (0.2, 23.4)

Disease location

​

​

Ileal only or ileocolonic, n (%)

23 (82.1)

21 (80.8)

Colonic only, n (%)

5 (17.9)

5 (19.2)

CRP (mg/L), median (min, max)

6 (0, 97)

6 (0, 93)

FCP (µg/g), median (min, max)

921 (139, 6685)

848 (81, 10581)

Baseline CS use, n (%)

5 (17.9)

6 (23.1)

Prior advanced therapy use, n (%)

7 (25.0)

7 (26.9)

5 of 6

Results: (Group 1)

IBUS-SAS, International Bowel Ultrasound Segmental Activity Score; BWT, bowel wall thickness; CDS, colour Doppler signal; SD, standard deviation.�Jairath V et al. ECCO 2026; (Abstract citation ID: jjaf231.1188, P1007).

5

6 of 6

Conclusions

    • In this interim analysis of a prospective open label trial, treatment with VDZ was associated with early improvement in IUS parameters in patients with CD

​

Significance to clinical practice

    • These results suggest that VDZ may be effective at controlling transmural inflammation in CD.
    • This trial may help to inform if a treat-2-target strategy guided by IUS is more effective than a strategy based on symptom/biochemical targets alone in CD

​

CD, Crohn’s disease; VDZ, vedolizumab; IUS, intestinal ultrasound.�Jairath V et al. ECCO 2026; (Abstract citation ID: jjaf231.1188, P1007).

6